Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.64 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.61 |
| ▸ | CTSL | P07711 | 4/20 | 0.60 |
| ▸ | CTSB | P07858 | 3/20 | 0.60 |
| ▸ | CTSS | P25774 | 2/20 | 0.60 |
| ▸ | MME | P08473 | 1/20 | 0.60 |
| ▸ | ECE1 | P42892 | 1/20 | 0.60 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13589982 | 1.00 | CTSK (0.64) | CTSKCAPN1CTSLCTSBCTSS | |
| SCHEMBL5827200 | 0.95 | CTSK (0.67) | CTSKCAPN1CTSLCTSBCTSS | |
| SCHEMBL31094975 | 0.95 | CTSK (0.67) | CTSKCAPN1CTSLCTSBCTSS | |
| SCHEMBL30643745 | 0.91 | CTSK (0.64) | CTSKCAPN1CTSLCTSBCTSS | |
| SCHEMBL31729514 | 0.91 | CAPN1 (0.68) | CTSKCAPN1CTSLCTSBCTSS | |
| SCHEMBL16770328 | 0.91 | CTSK (0.65) | CTSKCAPN1CTSLCTSBCTSS | |
| SCHEMBL25406813 | 0.91 | CTSK (0.77) | CTSKCAPN1CTSLCTSBCTSS | |
| SCHEMBL8823918 | 0.91 | CTSK (0.77) | CTSKCAPN1CTSLCTSBCTSS | |
| SCHEMBL20770085 | 0.91 | CTSK (0.77) | CTSKCAPN1CTSLCTSBCTSS | |
| SCHEMBL9697579 | 0.91 | MME (0.65) | CTSLMMEECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070196859-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070196859-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070154948-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-07-05 | — | — | US | disclosed |
| US-20070154948-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070196859-A1 | Novel antibacterial agents | ENGASE, PEPD, PGLS | CTSK 622/4885CAPN1 1267/4885CTSL 137/4885 |
| US-20070154948-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | CTSK 748/4885CAPN1 1236/4885CTSL 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.